Shanghai Rongtai Health Tech (603579) - Net Assets
Based on the latest financial reports, Shanghai Rongtai Health Tech (603579) has net assets worth CN¥2.89 Billion CNY (≈ $423.63 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.79 Billion ≈ $554.48 Million USD) and total liabilities (CN¥894.23 Million ≈ $130.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603579 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.89 Billion |
| % of Total Assets | 76.4% |
| Annual Growth Rate | 24.26% |
| 5-Year Change | 56.63% |
| 10-Year Change | 509.95% |
| Growth Volatility | 51.84 |
Shanghai Rongtai Health Tech - Net Assets Trend (2011–2025)
This chart illustrates how Shanghai Rongtai Health Tech's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Shanghai Rongtai Health Tech to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Rongtai Health Tech (2011–2025)
The table below shows the annual net assets of Shanghai Rongtai Health Tech from 2011 to 2025. For live valuation and market cap data, see Shanghai Rongtai Health Tech (603579) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.79 Billion ≈ $408.02 Million |
+38.34% |
| 2024-12-31 | CN¥2.02 Billion ≈ $294.95 Million |
+2.16% |
| 2023-12-31 | CN¥1.97 Billion ≈ $288.71 Million |
+5.50% |
| 2022-12-31 | CN¥1.87 Billion ≈ $273.65 Million |
+5.05% |
| 2021-12-31 | CN¥1.78 Billion ≈ $260.49 Million |
+7.87% |
| 2020-12-31 | CN¥1.65 Billion ≈ $241.49 Million |
+1.16% |
| 2019-12-31 | CN¥1.63 Billion ≈ $238.73 Million |
+8.90% |
| 2018-12-31 | CN¥1.50 Billion ≈ $219.23 Million |
+8.31% |
| 2017-12-31 | CN¥1.38 Billion ≈ $202.40 Million |
+202.57% |
| 2016-12-31 | CN¥457.14 Million ≈ $66.89 Million |
+46.16% |
| 2015-12-31 | CN¥312.77 Million ≈ $45.77 Million |
+60.19% |
| 2014-12-31 | CN¥195.25 Million ≈ $28.57 Million |
+49.59% |
| 2013-12-31 | CN¥130.52 Million ≈ $19.10 Million |
-8.04% |
| 2012-12-31 | CN¥141.94 Million ≈ $20.77 Million |
+6.49% |
| 2011-12-31 | CN¥133.29 Million ≈ $19.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Rongtai Health Tech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2780.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.31 Billion | 46.88% |
| Other Components | CN¥1.48 Billion | 53.12% |
| Total Equity | CN¥2.79 Billion | 100.00% |
Shanghai Rongtai Health Tech Competitors by Market Cap
The table below lists competitors of Shanghai Rongtai Health Tech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amata Corporation Public Company Limited
BK:AMATA-R
|
$605.77 Million |
|
AB Siauliu Bankas
F:ZH5
|
$605.89 Million |
|
HIMALAYA SHIPPING LTD DL1
F:J1X
|
$605.91 Million |
|
BizConf Telecom Co Ltd
SHE:300578
|
$606.37 Million |
|
Sturm Ruger & Company Inc
NYSE:RGR
|
$605.75 Million |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
$605.68 Million |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
$605.54 Million |
|
IFE Elevators Co Ltd
SHE:002774
|
$605.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Rongtai Health Tech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,014,115,666 to 2,785,374,219, a change of 771,258,553 (38.3%).
- Net income of 150,702,547 contributed positively to equity growth.
- Dividend payments of 61,928,831 reduced retained earnings.
- Other comprehensive income decreased equity by 179,445,948.
- Other factors increased equity by 861,930,785.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥150.70 Million | +5.41% |
| Dividends Paid | CN¥61.93 Million | -2.22% |
| Other Comprehensive Income | CN¥-179.45 Million | -6.44% |
| Other Changes | CN¥861.93 Million | +30.94% |
| Total Change | CN¥- | 38.29% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Rongtai Health Tech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.77x to 1.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.95 | CN¥20.59 | x |
| 2012-12-31 | CN¥0.99 | CN¥20.59 | x |
| 2013-12-31 | CN¥0.99 | CN¥20.59 | x |
| 2014-12-31 | CN¥1.45 | CN¥20.59 | x |
| 2015-12-31 | CN¥2.27 | CN¥20.59 | x |
| 2016-12-31 | CN¥3.31 | CN¥20.59 | x |
| 2017-12-31 | CN¥7.68 | CN¥20.59 | x |
| 2018-12-31 | CN¥8.18 | CN¥20.59 | x |
| 2019-12-31 | CN¥9.03 | CN¥20.59 | x |
| 2020-12-31 | CN¥9.33 | CN¥20.59 | x |
| 2021-12-31 | CN¥9.77 | CN¥20.59 | x |
| 2022-12-31 | CN¥10.75 | CN¥20.59 | x |
| 2023-12-31 | CN¥11.36 | CN¥20.59 | x |
| 2024-12-31 | CN¥10.18 | CN¥20.59 | x |
| 2025-12-31 | CN¥13.70 | CN¥20.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Rongtai Health Tech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.41%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.58%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.28x
- Recent ROE (5.41%) is below the historical average (18.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.02% | 5.61% | 1.49x | 1.68x | CN¥5.32 Million |
| 2012 | 4.86% | 2.07% | 1.37x | 1.71x | CN¥-7.15 Million |
| 2013 | 20.26% | 6.28% | 1.36x | 2.38x | CN¥13.08 Million |
| 2014 | 31.89% | 8.52% | 1.64x | 2.29x | CN¥42.27 Million |
| 2015 | 46.10% | 13.94% | 1.52x | 2.17x | CN¥111.75 Million |
| 2016 | 45.80% | 16.08% | 1.19x | 2.39x | CN¥161.52 Million |
| 2017 | 15.82% | 11.27% | 0.88x | 1.60x | CN¥79.49 Million |
| 2018 | 16.73% | 10.86% | 1.06x | 1.45x | CN¥100.24 Million |
| 2019 | 18.15% | 12.77% | 0.94x | 1.51x | CN¥132.69 Million |
| 2020 | 11.63% | 9.55% | 0.68x | 1.78x | CN¥27.06 Million |
| 2021 | 13.30% | 9.05% | 0.80x | 1.85x | CN¥58.70 Million |
| 2022 | 8.80% | 8.19% | 0.59x | 1.83x | CN¥-22.39 Million |
| 2023 | 10.30% | 10.93% | 0.55x | 1.72x | CN¥5.82 Million |
| 2024 | 9.53% | 12.02% | 0.43x | 1.86x | CN¥-9.47 Million |
| 2025 | 5.41% | 9.58% | 0.44x | 1.28x | CN¥-127.83 Million |
Industry Comparison
This section compares Shanghai Rongtai Health Tech's net assets metrics with peer companies in the Leisure industry.
Industry Context
- Industry: Leisure
- Average net assets among peers: $969,842,292
- Average return on equity (ROE) among peers: -3.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Rongtai Health Tech (603579) | CN¥2.89 Billion | 14.02% | 0.31x | $605.76 Million |
| China Bicycle Co Holdings Ltd (000017) | $17.28 Million | 15.07% | 2.13x | $332.21 Million |
| HL Corp Shenzhen (002105) | $597.06 Million | 0.71% | 1.41x | $278.68 Million |
| Goldlok Toys Holdings Guangdong Co Ltd (002348) | $1.06 Billion | -31.03% | 0.36x | $1.57 Billion |
| Guangdong Qunxing Toys Joint-Stock Co Ltd (002575) | $891.41 Million | -2.40% | 0.01x | $532.26 Million |
| Shanghai Yaoji Playing Card Co Ltd (002605) | $965.45 Million | 12.67% | 0.50x | $1.12 Billion |
| Xiamen Comfort Science&Technology Group Co Ltd (002614) | $217.49 Million | 21.16% | 1.94x | $428.07 Million |
| Guangzhou Pearl River Piano Group Co Ltd (002678) | $3.23 Billion | 5.10% | 0.29x | $934.20 Million |
| Shifeng Cultural Development Co Ltd (002862) | $283.43 Million | -61.66% | 1.34x | $345.15 Million |
| Impulse Qingdao Health Tech Co Ltd (002899) | $1.08 Billion | 3.65% | 0.26x | $487.05 Million |
| China Bicycle Co Holdings Ltd (200017) | $1.35 Billion | 2.23% | 1.18x | $51.61 Million |
About Shanghai Rongtai Health Tech
Shanghai Rongtai Health Technology Corporation Limited, together with its subsidiaries, engages in the research, design, development, production, and sale of massage equipment under the Rongtai and Momoda brands in China and internationally. The company offers massage chairs and accessories, neck massagers, eye massagers, massage backrests, massage belts, foot massagers, massage pads, and handhel… Read more